Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Victor de Ledinghen

Showing results (71-80 of 175) with videos related to

Pageof 18
Sort By:
BMC Gastroenterology|March 1, 2006
Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver diseaseVlad Ratziu, Julien Massard, Frederic Charlotte, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|February 8, 2014
Prevalence of renal abnormalities in chronic HBV infection: the HARPE studySabine Amet, Jean-Pierre Bronowicki, Dominique Thabut, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|February 21, 2018
Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection: A pooled analysisTarik Asselah, Hendrik Reesink, Jan Gerstoft, et al.
The American Journal of Gastroenterology|April 7, 2011
A new combination of blood test and fibroscan for accurate non-invasive diagnosis of liver fibrosis stages in chronic hepatitis CJérôme Boursier, Victor de Ledinghen, Jean-Pierre Zarski, et al.
BMC Gastroenterology|November 14, 2006
Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver diseaseThierry Poynard, Vlad Ratziu, Frederic Charlotte, et al.
Hepatology (Baltimore, Md.)|November 11, 2010
A protective role for CD154 in hepatic steatosis in miceJulien Villeneuve, Sébastien Lepreux, Audrey Mulot, et al.
Journal of Hepatology|December 15, 2010
A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitisVlad Ratziu, Victor de Ledinghen, Fréderic Oberti, et al.
Gastro Hep Advances|August 12, 2024
External Validation of LCR1-LCR2, a Multivariable Hepatocellular Carcinoma Risk Calculator, in a Multiethnic Cohort of Patients With Chronic Hepatitis BThierry Poynard, Jean Marc Lacombe, Olivier Deckmyn, et al.
JHEP Reports : Innovation in Hepatology|June 18, 2021
External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCVThierry Poynard, Jean Marc Lacombe, Olivier Deckmyn, et al.
BMC Gastroenterology|October 17, 2007
Meta-analyses of FibroTest diagnostic value in chronic liver diseaseThierry Poynard, Rachel Morra, Philippe Halfon, et al.
Pageof 18

Showing results (71-80 of 175) with videos related to

Sort By:
Pageof 18
BMC Gastroenterology|March 1, 2006
Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver diseaseVlad Ratziu, Julien Massard, Frederic Charlotte, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|February 8, 2014
Prevalence of renal abnormalities in chronic HBV infection: the HARPE studySabine Amet, Jean-Pierre Bronowicki, Dominique Thabut, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|February 21, 2018
Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection: A pooled analysisTarik Asselah, Hendrik Reesink, Jan Gerstoft, et al.
The American Journal of Gastroenterology|April 7, 2011
A new combination of blood test and fibroscan for accurate non-invasive diagnosis of liver fibrosis stages in chronic hepatitis CJérôme Boursier, Victor de Ledinghen, Jean-Pierre Zarski, et al.
BMC Gastroenterology|November 14, 2006
Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver diseaseThierry Poynard, Vlad Ratziu, Frederic Charlotte, et al.
Hepatology (Baltimore, Md.)|November 11, 2010
A protective role for CD154 in hepatic steatosis in miceJulien Villeneuve, Sébastien Lepreux, Audrey Mulot, et al.
Journal of Hepatology|December 15, 2010
A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitisVlad Ratziu, Victor de Ledinghen, Fréderic Oberti, et al.
Gastro Hep Advances|August 12, 2024
External Validation of LCR1-LCR2, a Multivariable Hepatocellular Carcinoma Risk Calculator, in a Multiethnic Cohort of Patients With Chronic Hepatitis BThierry Poynard, Jean Marc Lacombe, Olivier Deckmyn, et al.
JHEP Reports : Innovation in Hepatology|June 18, 2021
External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCVThierry Poynard, Jean Marc Lacombe, Olivier Deckmyn, et al.
BMC Gastroenterology|October 17, 2007
Meta-analyses of FibroTest diagnostic value in chronic liver diseaseThierry Poynard, Rachel Morra, Philippe Halfon, et al.
Pageof 18